23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
31 oct. 2023 08h00 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading genetic health and biopharmaceutical company, today launched Health Action Plan,...
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
30 oct. 2023 08h00 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 30, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”) today announced a new, non-exclusive data license with GSK plc (LSE/NYSE: GSK) which...
23andMe to Report FY2024 Second Quarter Financial Results
25 oct. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
27 sept. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading human genetics and biopharmaceutical company, today announced two poster...
23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program
14 sept. 2023 07h00 HE
|
23andMe, Inc.
23andMe will offer its Health + Ancestry Service at no cost for up to 1,000 eligible* participants who are 18 years or older and have African ancestry or ancestry from a region where sickle cell...
23andMe Granted New FDA Clearance to Report Additional BRCA Variants
31 août 2023 17h28 HE
|
23andMe, Inc.
510(k) clearance will allow 23andMe to report an additional 41 genetic variants in the BRCA1 and BRCA2 genes that increase risk for breast, ovarian, prostate and pancreatic cancer Many of these...
23andMe Reports FY2024 First Quarter Financial Results
08 août 2023 16h05 HE
|
23andMe, Inc.
Reaffirmed Full Year Revenue Guidance and Raised Full Year Guidance for Net Loss and Adjusted EBITDA Deficit Webcast at 4:30 pm ET, August 8, 2023 SOUTH SAN FRANCISCO, Calif., Aug. 08,...
23andMe to Report FY2024 First Quarter Financial Results
25 juil. 2023 16h05 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people...
23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin
20 juil. 2023 09h23 HE
|
23andMe, Inc.
23andMe is the first and only direct-to-consumer product to offer a suite of FDA-authorized pharmacogenetics reports, with medication insights Lipid-lowering statins are one of the most commonly...
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
21 juin 2023 07h00 HE
|
23andMe, Inc.
SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report as part...